New insider activity at AnaptysBio ( (ANAB) ) has taken place on December 23, 2025.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Director J. Anthony Ware has sold 3,900 shares of AnaptysBio stock in a recent transaction, with the sale totaling $193,323 in value.
Recent Updates on ANAB stock
In the last day, AnaptysBio (ANAB) has been in focus as several analysts updated their valuation frameworks around the stock. Guggenheim raised its valuation primarily because of positive Phase I clinical data for ANB033, which led the firm to expand its assumed commercial potential in celiac disease and other indications, and because it now attributes substantial value to expected royalties from the cancer drug Jemperli (dostarlimab). In contrast, Barclays and Stifel both trimmed their price targets as part of broad, forward-looking resets of their biotechnology coverage into 2026, reflecting updated models and sector‑wide assumptions rather than ANAB‑specific negative news. Separately, AnaptysBio’s ongoing legal complaint against Tesaro and GSK over alleged breaches of their license agreement for dostarlimab underscores the strategic importance of that asset and potential impact on future economics, which also factors into how analysts frame the company’s long‑term value. No explicit 24‑hour price move is given in the articles, but the day’s news flow centers on these revised valuations and the company’s pipeline and legal positioning.
Spark’s Take on ANAB Stock
According to Spark, TipRanks’ AI Analyst, ANAB is a Neutral.
AnaptysBio’s overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and a precarious balance sheet. While technical indicators show bullish momentum, the stock’s valuation remains unattractive due to negative earnings. Corporate events present mixed implications, with legal challenges offset by strategic initiatives like stock buybacks and business separation plans.
To see Spark’s full report on ANAB stock, click here.
More about AnaptysBio
YTD Price Performance: 276.72%
Average Trading Volume: 581,520
Technical Sentiment Signal: Buy
Current Market Cap: $1.36B